Clinical Trials

86 enrolled

Leukemia, Hairy Cell

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02629809 2026-03-06

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

81 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04169737 2026-02-24

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05536349 2026-02-24

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

60 enrolled

Leukemia

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

30 enrolled

Leukemia, Leukemia, Hairy Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-02-04

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06333262 2026-01-21

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

70 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04505254 2025-12-26

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02666898 2025-11-26

ICLL07GAI

135 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04447768 2025-10-14

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

100 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06849713 2025-09-25

BOSon

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03824483 2025-09-23

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04722172 2025-08-27

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04515238 2025-06-10

CLL2-BZAG

42 enrolled

Phase 2 Not yet recruiting

Leukemia, B-Cell

NCT07003464 2025-06-04

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

46 enrolled

Leukemia, B-Cell

NCT06544785 2024-10-24

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

106 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04908228 2023-10-03

FIGHT

53 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03145480 2023-06-01

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Phase 2 Terminated

3 enrolled 5 charts

Leukemia

NCT02758665 2023-01-17

CLL2-GiVe

41 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02225275 2022-09-28

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

9 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05322733 2022-04-19

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Phase 2 Unknown

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02968563 2022-01-21

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

35 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02983617 2021-12-21

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

36 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

3 enrolled

Disease, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02320487 2020-02-11

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

102 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02071225 2020-02-07

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

72 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02371590 2018-02-23

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Phase 2 Withdrawn

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01414205 2017-04-17

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

80 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01868893 2017-04-17

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

20 enrolled 8 charts